Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Amyloid Cardiomyopathy: full-pipeline trial registry
2 of 4 indexed Amyloid Cardiomyopathy trials are currently recruiting.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Amyloid Cardiomyopathy: 4 US clinical trials tracked, 2 recruiting.
Amyloid Cardiomyopathy is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Eidos Therapeutics, a BridgeBio company, running 2 of these trials.
Enrollment posture brief
Registry condition amyloid-cardiomyopathy
OPEN 2 | RECR 50% | LATE 1 | EARLY 1 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Amyloid Cardiomyopathy lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Amyloid Cardiomyopathy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Amyloid Cardiomyopathy is recruiting above its size-band peers.
2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Eidos Therapeutics, a BridgeBio company
NCT06563895
Exercise Training in Transthyretin Cardiac Amyloidosis
Brigham and Women's Hospital
NCT05797857
Open-Label Study of AG10 in Patients with Cardiomyopathy
Eidos Therapeutics, a BridgeBio company
NCT03536767
Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis
The Cleveland Clinic
NCT03431896
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Amyloid Cardiomyopathy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Amyloid Cardiomyopathy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Amyloid Cardiomyopathy page
4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Amyloid Cardiomyopathy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eidos Therapeutics, a BridgeBio company sponsors the most Amyloid Cardiomyopathy trials on record, review their full trial history before evaluating a specific study. See Eidos Therapeutics, a BridgeBio company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Amyloid Cardiomyopathy condition card totals 4 registered trials; most-linked intervention AG10; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.